Menarini’s strategy

Economic-financial daily Il Sole 24 Ore reported a long statement by Menarini chairman Lucia Aleotti, who indicated some guidelines for the growth of the Italy-based pharmaceutical group. The company is determined to pursue an organic growth, yet it doesn’t rule out an international acquisition, Aleotti said. This strategy, already designed in 2011, consists of providing a wider treatment offer – the same strategy has already been applied to oncological and diagnostic research – with the objective of entering the business of technologies for vaccine production. Aleotti took the opportunity to rule out both targeting an IPO and other important actors joining the body of shareholders. The Menarini group, with approximately 17,000 employees, generated about €3.46bn in revenue in 2016, 73% of which abroad (+4% vs 2015) and had an operating profit of €411m.
(Source Il Sole 24 Ore)